This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Acorda (ACOR) Beats Earnings & Revenues Estimates in Q4
by Zacks Equity Research
Acorda (ACOR) reports lower-than-expected loss in the fourth quarter while revenues beat estimates.
What's in Store for Acorda (ACOR) This Earnings Season?
by Zacks Equity Research
During Acorda's (ACOR) Q4 earnings call, investor focus will be on the sales uptake of its newly-launched Parkinson's disease drug Inbrija.
Earnings Preview: Acorda Therapeutics (ACOR) Q4 Earnings Expected to Decline
by Zacks Equity Research
Acorda (ACOR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Acorda (ACOR) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Acorda (ACOR) stock based on the movements in the options market lately.
Acorda Therapeutics (ACOR) in Focus: Stock Moves 5.7% Higher
by Zacks Equity Research
Acorda Therapeutics (ACOR) shares rose nearly 6% in the last trading session, amid huge volumes.
Acorda (ACOR) Down 13.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Acorda (ACOR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Acorda (ACOR) Down More Than 80% Year to Date: Here's Why
by Zacks Equity Research
Acorda's (ACOR) lead MS drug Ampyra is hit by generic competition in the United States, which is hurting the company's top line of late. Parkinson's disease drug Inbrija seems an ideal replacement.
Zoetis (ZTS) Beats on Earnings in Q3, Reports In-Line Sales
by Zacks Equity Research
Zoetis (ZTS) beats earnings estimates, while sales are in line in the third quarter of 2019.
Horizon Therapeutics' (HZNP) Q3 Earnings Beat Estimates
by Zacks Equity Research
Horizon Therapeutics (HZNP) beats earnings and sales estimates in the third quarter of 2019.
Esperion (ESPR) Reports Wider-Than-Expected Loss in Q3
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports mixed third-quarter results.
Geron (GERN) Q3 Earnings Beat Estimates, Stock Gains 4.1%
by Zacks Equity Research
Geron (GERN) reports encouraging third-quarter 2019 results. Operating expenses increase on a year-over-year basis.
Perrigo (PRGO) Beats on Q3 Earnings, Tightens '19 EPS View
by Zacks Equity Research
Perrigo (PRGO) reports mixed third-quarter 2019 results. The Rx segment continues to witness recovery. Stock down.
Intercept (ICPT) Earnings and Sales Miss Estimates in Q3
by Zacks Equity Research
Intercept (ICPT) reports a wider-than-expected loss and misses on sales in the third quarter of 2019.
Acorda (ACOR) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Acorda (ACOR) posts narrower-than-expected loss with revenues also topping estimates in the third quarter. Inbrija is also off to a promising start with sales rising sequentially.
Agenus (AGEN) Q3 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Agenus (AGEN) posts narrower-than-expected loss and beats sales estimates in the third quarter of 2019.
Acorda Therapeutics (ACOR) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Acorda (ACOR) delivered earnings and revenue surprises of 9.80% and 7.53%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
AMAG Q3 Loss Wider Than Expected, Revenues Lag Estimates
by Zacks Equity Research
AMAG disappoints investors with earnings and sales miss in the third quarter.
Repligen (RGEN) Beats on Q3 Earnings, Lifts 2019 Guidance
by Zacks Equity Research
Repligen (RGEN) rides high on earnings and revenue beat in the third quarter of 2019. The company also raises 2019 guidance.
Agios' (AGIO) Q3 Loss Narrower Than Expected, Revenues Miss
by Zacks Equity Research
Although Agios (AGIO) betters loss estimates in Q3, its revenues lag the same. The company's wholly owned leukemia drug Tibsovo sees a rise in sales sequentially.
Immunomedics (IMMU) Reports Wider-Than-Expected Loss in Q3
by Zacks Equity Research
Immunomedics' (IMMU) loss lags estimates in Q3. The company fails to generate any revenues at the same time.
Vertex (VRTX) Q3 Earnings Beat, Revenues Lag Estimates
by Zacks Equity Research
Vertex (VRTX) encourages investors with better-than-expected earnings in Q3. However, the top line misses the mark.
Medicines Company (MDCO) Incurs Wider-Than-Expected Q3 Loss
by Zacks Equity Research
The Medicines Company (MDCO) misses earnings estimates in Q3. The company is progressing well with its sole pipeline candidate, inclisiran.
Insmed (INSM) in Focus: Stock Moves 7.1% Higher
by Zacks Equity Research
Insmed (INSM) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Acorda Therapeutics (ACOR) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Acorda (ACOR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Acorda (ACOR) to Post Q3 Earnings: What's in the Cards?
by Zacks Equity Research
During Acorda's (ACOR) third-quarter earnings call, investor focus will be on the sales uptick of its newly launched Parkinson's disease drug Inbrija.